Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Extension Study of Theophylline for Treatment of Pseudohypoparathyroidism

NCT04240821 is registered in ClinicalTrials.gov with Jaclyn Tamaroff as lead sponsor.

NCT NCT04240821
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04240821 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Extension Study of Theophylline for Treatment of Pseudohypoparathyroidism
Lead sponsor
Jaclyn Tamaroff
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
May 22, 2020
Completion date
December 31, 2026
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

albright hereditary osteodystrophy, pseudohypoparathyroidism, pseudohypoparathyroidism type 1a